1.Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomised Phase II study.
Reich K1, Graff O2, Mehta N2. Br J Dermatol. 2016 Jan 22. doi: 10.1111/bjd.14401. [Epub ahead of print]
BACKGROUND: Palmoplantar pustulosis (PPP) is an inflammatory, debilitating skin disease. Topical drugs and systemic immunosuppressive agents are often ineffective. Previous uncontrolled studies have suggested that alitretinoin could be a meaningful treatment option for PPP.
2.Alitretinoin: treatment for refractory palmoplantar keratoderma.
Park HK1, Kim EJ1, Ko JY1. Br J Dermatol. 2015 Nov 30. doi: 10.1111/bjd.14327. [Epub ahead of print]
Mal de Meleda (MDM) is an autosomal recessive form of palmoplantar keratoderma caused by mutations in the ARS gene, encoding SLURP-1.1 It has been reported that etretinate and acitretin, which are aromatic retinoids, are effective treatment modalities for MDM.2 However, early and long-term use of these retinoids are associated with several well-known adverse effects, such as dryness, teratogenicity and liver toxicity. This article is protected by copyright. All rights reserved.
3.Alitretinoin in Dermatology-An Update.
Bubna AK1. Indian J Dermatol. 2015 Sep-Oct;60(5):520. doi: 10.4103/0019-5154.164426.
Alitretinoin is a pan retinoic acid agonist. It was initially used as 0.1% gel in the management of localized Kaposi's sarcoma. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other retinoid responsive dermatosis that have demonstrated remission post usage of systemic alitretinoin. With a better toxicity profile, compared to the other systemic retinoids, alitretinoin could be considered a valuable treatment option in the near future for the treatment of these dermatologic disorders.